Cabaletta Bio, Inc.
CABA
Jodie situation report
Cabaletta Bio, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 12 directly disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NRIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind CABA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PENNPENN Entertainment, Inc.supplierNov 10, 2025 ▾
“For supply of lentiviral vector for the clinical and commercial manufacturing of rese-cel, we are currently working with Oxford Biomedica (UK) Limited, or Oxford, where we are advancing BLA readiness activities, and have previously manufactured lentiviral vec…”
PENNPENN Entertainment, Inc.partnerMar 23, 2026 ▾
“The longstanding and highly productive partnership between our co-founders has been complemented by additional management experience that brings a successful history of translating academic cellular therapy research from Penn and elsewhere into commercially s…”
Depended on by
ARTVArtiva Biotherapeutics, Inc.competitorMay 8, 2026 ▾
“Our known biopharmaceutical competitors that are developing allogeneic NK, CAR-NK, or CAR-T cell therapies or T-cell engaging bispecific antibodies include, but may not be limited to, the following: Adicet Bio, Inc., Allogene Therapeutics, Inc., Amgen Inc., A…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CABA is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.